Type IIA Secretory PLA2-Mediated Delayed PGE2 Biosynthesis is Regulated by the Products of the Cytosolic PLA2

  • Hiroshi Kuwata
  • Shinji Yamamoto
  • Yoshihito Nakatani
  • Makoto Murakami
  • Ichiro Kudo
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 507)

Abstract

Phospholipase A2s (PLA2s) comprises a growing family of enzymes that hydrolyze membrane glycerophospholipids at the sn-2 position, generating free fatty acids containing arachidonic acid (AA) and lysophospholipids. The released AA is converted to prostaglandins (PGs) and leukotrienes by cyclooxygenases (COXs) and 5lipoxygenases (5-LOX), respectively. Lysophospholipids themselves often act as lipid mediators and are also metabolized to other bioactive lipids, such as platelet-activating factor. To date, more than ten PLA2 1 and two COX2 isozymes have been identified in mammals. Type IIA secretory PLA2 (sPLA2-IIA) is a 14-kDa PLA2 that requires millimolar levels of calcium for its activation and is induced by various stimuli such as proinflammatory cytokines and endotoxin in many cell types36. sPLA2-IIA is referred to as the inflammatory-type PLA2, since it is highly expressed in the plasma and synovial fluids of patients with various inflammatory diseases such as rheumatoid arthritis, pancreatitis, Crohn’s disease, and endotoxic shock6 as well as various cancers’. Cytosolic PLA2 (cPLA2: type IV) is an 85 kDa PLA2 that is constitutively expressed in various cells and tissues89. This enzyme preferentially hydrolyzes AA from membrane phospholipids and requires micromolar calcium for its activation. Both the phosphorylation and calcium-dependent translocation of cPLA2 to the membranes are essential for its activation10. Current evidence suggests that the existence of two kinetically distinct PG-biosynthetic responses, the immediate and delayed phases, implies the recruitment of different sets of biosynthetic enzymes to this pathway11.

Keywords

Arthritis Aspirin Pancreatitis Ketone Prostaglandin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    E. A. Dennis, The growing phospholipase A2 superfamily of signal transduction enzymes, Trends Biochem. Sci. 22, 1 (1997)PubMedCrossRefGoogle Scholar
  2. 2.
    W. L. Smith, R. M. Garavito, and D. L. DeWitt, Prostaglandin endoperoxide H synthases (cyclooxygenases)1 and -2, J. Biol. Chem. 271, 33157 (1996)PubMedCrossRefGoogle Scholar
  3. 3.
    H. Kuwata, Y. Nakatani, M. Murakami, and I. Kudo, Cytosolic phospholipase A2 is required for cytokine-induced expression of type HA secretory phospholipase A2 that mediates optimal cyclooxygenase-2dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts, J. Biol. Chem. 273, 1733 (1998)PubMedCrossRefGoogle Scholar
  4. 4.
    H. Naraba, M. Murakami, H. Matsumoto, S. Shimbara, A. Ueno, I. Kudo, and S. Oh-ishi, Segregated coupling of phospholipases A2, cyclooxygenases, and terminal prostanoid synthases in different phases of prostanoid biosynthesis in rat peritoneal macrophages, J. Immunol. 160, 2974 (1998)PubMedGoogle Scholar
  5. 5.
    M. Murakami, H. Kuwata, Y. Amakasu, S. Shimbara, Y. Nakatani, G. Atsumi, and I. Kudo, Prostaglandin E, amplifies cytosolic phospholipase A2- and cyclooxygenase-2-dependent delayed prostaglandin E2 generation in mouse osteoblastic cells: enhancement by secretory phospholipase A2, J. Biol. Chem. 272, 19891 (1997)PubMedCrossRefGoogle Scholar
  6. 6.
    M. Murakami, Y. Nakatani, G. Atsumi, K. Inoue, and I. Kudo, Regulatory functions of phospholipase A2, Crit. Rev. Immunol. 17, 225 (1997)PubMedCrossRefGoogle Scholar
  7. 7.
    T. Abe, K. Sakamoto, H. Kamohara, Y. Hirano, N. Kuwahara, and M. Ogawa, Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer, Int. J. Cancer. 74, 245 (1997)PubMedCrossRefGoogle Scholar
  8. 8.
    I. Kudo, M. Murakami, S. Hara, and K. Inoue, Mammalian non-pancreatic phospholipases A2, Biochim. Biophys. Acta 1170, 217 (1993)PubMedCrossRefGoogle Scholar
  9. 9.
    J. D. Clark, L. L. Lin, R. W. Kriz, C. S. Ramesha, L. A. Sultzman, A. Y. Lin, N. Milona, J. L. Knopf, A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2)-dependent translocation domain with homology to PKC and GAP, Cell 65, 1043 (1991)PubMedCrossRefGoogle Scholar
  10. 10.
    L. L. Lin, A. Y. Lin, and J. L. Knopf, Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid, Proc. Natl. Acad. Sci. U. S. A. 89, 6147 (1992)PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    K. Tada, M. Murakami, T. Kambe, I. Kudo, Induction of cyclooxygenase-2 by secretory phospholipases A2 in nerve growth factor-stimulated rat serosal mast cells is facilitated by interaction with fibroblasts and mediated by a mechanism independent of their enzymatic functions, J. Immunol. 161, 5008 (1998)PubMedGoogle Scholar
  12. 12.
    M. Murakami, T. Kambe, S. Shimbara, I. Kudo, Functional coupling between various phospholipase A2s and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways, J. Biol. Chem. 274, 3103 (1999)PubMedCrossRefGoogle Scholar
  13. 13.
    H. Shinohara, M. A. Balboa, C. A. Johnson, J. Balsinde, E. A. Dennis, Regulation of delayed prostaglandin production in activated P388D, macrophages by group IV cytosolic and group V secretory phospholipase A2s, J. Biol. Chem. 274, 12263 (1999)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Hiroshi Kuwata
    • 1
  • Shinji Yamamoto
    • 1
  • Yoshihito Nakatani
    • 1
  • Makoto Murakami
    • 1
  • Ichiro Kudo
    • 1
  1. 1.Department of Health Chemistry School of Pharmaceutical Sciences ShowaUniversity 1-5-8 HatanodaiShinagawa-kuJapan

Personalised recommendations